Humana just posted a quarter that, on paper, looks pretty good. The health insurer came in ahead of Wall Street expectations on both earnings and revenue for the second quarter. The company posted net income of $694 million ($5.73 per share), compared to $545 million ($4.51 per share) a year ago. After removing costs such as amortization and impairment, Humana's adjusted profit came to $7.61 per share.
Total revenue rose to $40.87 billion, compared to $32.39 billion in the same quarter last year.
The beat came from two places. Humana's core insurance business performed well, and its CenterWell healthcare services unit kept humming. Medical and pharmacy costs tracked in line with the company's expectations for both new and existing members. CFO Celeste Mellet said inpatient hospital visits were "slightly favorable," with that trend most apparent among members who get care through value-based providers.
Humana's medical benefit ratio - the portion of premiums used for medical claims - was 91.2% in Q2. That matches both analyst estimates and the company's own internal forecast. A year ago, that number was 89.9%.
So if the numbers are good, why did the stock take a more than 6% dive the day the results came out?
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
The answer is in the outlook. That is the same target it set months ago.
The problem is that some other big health insurers have been raising their outlooks lately. Analysts at Cantor Fitzgerald called the decision to hold steady a "disappointment." Investors had been hoping for a similar upgrade.
The company also pointed to a few headwinds. Mellet pointed out that pharmacy-related medical costs are still "very elevated," largely due to pharmaceutical pricing and the introduction of new drugs. She also said these expenses are projected to increase a bit in 2027 relative to 2026.
The catch: beating the quarter is nice, but what matters to the market is what happens next. And right now, Humana is signaling patience, not acceleration.
CFO Celeste Mellet tried to calm the room. She told analysts that medical cost trends are getting more predictable. "At this point, we call medical costs more stable," she said. She credited a mix of stabilizing trends and the company's own efforts to improve member health.
When asked what is driving that stability, Mellet said, "I think that it's a combination of just [medical cost] trend stabilizing and then our actions as well to help drive better health outcomes for our members and our patients."
That matters because Humana is one of the biggest players in Medicare Advantage, the privately run version of Medicare that a lot of older Americans use. Those plans are heavily regulated, and the company needs to keep costs predictable to make consistent profits.
Humana is not giving up on better margins. The company laid out a clear plan to improve profitability in its Medicare Advantage business starting in 2027. The company aims to achieve a pretax profit margin of 3% or more on a consistent basis by 2028. To get there, it plans to add more members, improve its plan quality ratings, stay disciplined on pricing, and keep costs under control.
For investors, the story here is a long game. Humana beat expectations but refused to get ahead of itself. The stock took a hit because the market wanted more good news now.
But stable costs and a plan to improve margins over the next couple of years give the company room to work.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
